Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 19/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 15/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14235546 | 0.96 | DGAT1 (0.64) | DGAT1KCNH2ADORA2ACYP2C9SOAT1 | |
| SCHEMBL14235545 | 0.94 | DGAT1 (0.61) | DGAT1KCNH2ADORA2ACYP2C9SOAT1 | |
| SCHEMBL14235542 | 0.89 | DGAT1 (0.68) | DGAT1KCNH2ADORA2ACYP2C9SOAT1 | |
| SCHEMBL14952454 | 0.89 | DGAT1 (0.63) | DGAT1KCNH2ADORA2ACYP2C9SOAT1 | |
| SCHEMBL14235538 | 0.86 | DGAT1 (0.69) | DGAT1KCNH2ADORA2ACYP2C9SOAT1 | |
| SCHEMBL14235529 | 0.85 | DGAT1 (0.66) | DGAT1KCNH2ADORA2ACYP2C9SOAT1 | |
| SCHEMBL14235368 | 0.85 | DGAT1 (0.66) | DGAT1KCNH2ADORA2ACYP2C9SOAT1 | |
| SCHEMBL14235375 | 0.83 | DGAT1 (0.53) | DGAT1KCNH2ADORA2ACYP2C9SOAT1 | |
| SCHEMBL14235544 | 0.83 | DGAT1 (0.63) | DGAT1KCNH2ADORA2ACYP2C9SOAT1 | |
| SCHEMBL14235531 | 0.83 | DGAT1 (0.68) | DGAT1KCNH2ADORA2ACYP2C9SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140088124-A1 | IMIDAZOLE DERIVATIVES | INTERVET INC. | 2014-03-27 | — | — | US | disclosed |
| US-20140088124-A1 | IMIDAZOLE DERIVATIVES | INTERVET INC. | 2014-03-27 | — | — | US | disclosed |
| WO-2012164071-A1 | IMIDAZOLE DERIVATIVES | INTERVET INTERNATIONAL B.V. (NL) | 2012-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088124-A1 | IMIDAZOLE DERIVATIVES | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885KCNH2 2689/4885ADORA2A 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.